相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
Shaji K. Kumar et al.
BLOOD (2011)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
Prashant Kapoor et al.
MAYO CLINIC PROCEEDINGS (2010)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji K. Kumar et al.
MAYO CLINIC PROCEEDINGS (2009)
High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
Fenghuang Zhan et al.
BLOOD (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?
W. J. Chng et al.
LEUKEMIA (2008)
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
P. Moreau et al.
LEUKEMIA (2007)
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
John D. Shaughnessy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
Wee J. Chng et al.
CANCER RESEARCH (2007)
Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma
Wee J. Chng et al.
GENES CHROMOSOMES & CANCER (2006)
Prognostic factors for hyperdiploid-myeloma:: effects of chromosome 13 deletions and IgH translocations
W Chng et al.
LEUKEMIA (2006)
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
L. Chiecchio et al.
LEUKEMIA (2006)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
MA Gertz et al.
BLOOD (2005)
A validated FISH trisony index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
WJ Chng et al.
BLOOD (2005)
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma
S Wuilleme et al.
LEUKEMIA (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
N Kröger et al.
BLOOD (2004)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
T Facon et al.
BLOOD (2001)
分享论文
